BackgroundRespiratory syncytial virus (RSV) infections in lung transplant recipients (LTRs) have been associated with bronchiolitis obliterans syndrome (BOS). However, limited data exists regarding the association of RSV with other types of rejection.MethodsThis retrospective study of all RSV-infected LTRs at Duke University from January 2013 to May 2017 examined acute cellular rejection (ACR), acute antibody mediated rejection (AMR), new human leukocyte antigen (HLA) detection, new donor-specific antigen (DSA) detection, new BOS development and BOS progression at 1 year after RSV infection. Early and late RSV was defined as infection occurring ≤ or >180 days post lung transplant, respectively. Logistic regression was performed to adjust risk of rejection.ResultsOf 114 RSV-infected LTRs, 20 and 94 had early and late infection respectively. The cohort differs regarding underlying prior BOS, site of infection and RBV treatment (see table). Overall 1-year ACR after RSV infection was 44.7% (75% vs. 38.3% in early and late groups, respectively). Patients with early RSV infection had significantly higher rate of new HLA and DSA detection (see table). After adjusting by infection site and RBV exposure, the odd ratios (OR) for new HLA detection for patients with early RSV was 5.4 [1.4, 20.7]. Both oral and inhaled RBV did not decrease the OR for ACR after adjusting for infection and timing of RSV infection after lung transplantation.ConclusionOur data showed RSV infection was associated with very high rates of ACR in both early and later RSV groups. Patients with early RSV had higher rates of new HLA and DSA detection.Early RSV N = 20 (%)Late RSV N = 94 (%) P-valueUnderlying BOS prior to RSV infection024 (25.5)0.01Site of infection0.03Upper tract3 (15)41 (43.6)Lower tract9 (45)36 (38.3)Asymptomatic8 (40)17 (18.1)Treatment<0.001Oral RBV4 (20)66 (70.2)Inhaled RBV10 (50)22 (23.4)Supportive care6 (30)6 (6.4)Concomitant IVIG3 (15)18 (19.4)0.65RejectionsACR15 (75)36 (38.3)0.03Median episodes of ACR within 1 year after RSV infection (range)1 (1–5)1 (1–3)0.38AMR3 (15)4 (4.3)0.07New detection of:HLA7 (35)10 (10.6)0.005DSA6/7 (85.7)3/10 (30)0.03BOS4/20 (20)19/70(27.1)0.52BOS progression (patients with prior BOS)-9/24 (37.5)-Disclosures R. Miller, scynexis: Investigator, Research support.